Lung Neuroendocrine Neoplasm
Associated Genetic Biomarkers
NCI Definition: A low, intermediate, or high grade malignant neoplasm with neuroendocrine differentiation that arises from the lung. This category includes typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma, and combined carcinoma. 
Lung neuroendocrine neoplasms most frequently harbor alterations in TP53, RB1, KMT2D, CREBBP, and NOTCH1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in lung neuroendocrine neoplasm .
There are 6 clinical trials for lung neuroendocrine neoplasm, of which 6 are open and 0 are completed or closed. Of the trials that contain lung neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).
177lu-opsc001, incomplete freund's adjuvant, and octreotide acetate are the most common interventions in lung neuroendocrine neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.